Antibodies

8 November 2016

First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID)

6 November 2016

Glenmark Pharmaceuticals’ Experimental GBR 1302-BEAT™ Demonstrates Potent Anti-Tumor Activity in Preclinical Data Presented at the ESMO Symposium on Immuno-Oncology

6 November 2016

FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis

4 November 2016

ProMIS Neurosciences announces five novel antibody products meeting ideal target profile for Alzheimer’s disease

4 November 2016

Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting

4 November 2016

Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition

2 November 2016

OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

2 November 2016

Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA(R) (abatacept)

1 November 2016

Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor

1 November 2016

Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990)

31 October 2016

European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

30 October 2016

Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis

28 October 2016

AstraZeneca head and neck cancer trials

27 October 2016

Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab

27 October 2016

Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)

27 October 2016

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

26 October 2016

Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

26 October 2016

Atreca Describes Ebola Antibody Research Findings in Collaboration with Emory University

26 October 2016

Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas

25 October 2016

Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial

25 October 2016

New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

25 October 2016

Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer

25 October 2016

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations

24 October 2016

Mersana Announces FDA Clearance of IND Application for Lead Antibody-Drug Conjugate XMT-1522

24 October 2016

First Traumakine® Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial

23 October 2016

U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer

23 October 2016

FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence

21 October 2016

Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients

21 October 2016

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

20 October 2016

Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins